A variety of both classical agents (i.e., sulphonylureas and metformin) and newer agents (i.e., incretin-based therapies and sodium-glucose cotransporter-2 inhibitors) are recommended by various international guidelines for the treatment of diabetes mellitus [16]. Here, SLC5A2 is linked to diabetes mellitus.